MEPITIOSTANE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H40O2S
Molecular Weight	404.649
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@H](OC3(CCCC3)OC)[C@@]1(C)CC[C@@]4([H])[C@@]2([H])CC[C@@]5([H])C[C@@H]6S[C@@H]6C[C@]45C

InChI

InChIKey=IVDYZAAPOLNZKG-KWHRADDSSA-N

InChI=1S/C25H40O2S/c1-23-13-10-19-17(7-6-16-14-20-21(28-20)15-24(16,19)2)18(23)8-9-22(23)27-25(26-3)11-4-5-12-25/h16-22H,4-15H2,1-3H3/t16-,17-,18-,19-,20-,21+,22-,23-,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H40O2S
Molecular Weight	404.649
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.nichiiko.co.jp/data2/00910/04_interview/TDN-D-40(I1).pdf
Curator's Comment: description was created based on several sources, including, https://www.ncbi.nlm.nih.gov/pubmed/26247800

Mepitiostane is a epitiostanol prodrug that was developed in Japan by Shionogi. The drug is approved and used exclusively in Japan for the treatment of breast carcinoma and anemia associated with renal failure. Upon administration mepitiostane is metabolized to the active metabolite which binds to and inhibits estrogen receptors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 75 Target ID: CHEMBL2093866 Sources: http://www.nichiiko.co.jp/data2/00910/04_interview/TDN-D-40(I1).pdf	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: http://www.nichiiko.co.jp/data2/00910/04_interview/TDN-D-40(I1).pdf	Primary		Approved 8429	THIODERON Approved Use For the treatment of breast cancer and anemia associated with renal failure. Launch Date 1979
Anemia in renal failure 1 Sources: http://www.nichiiko.co.jp/data2/00910/04_interview/TDN-D-40(I1).pdf	Primary		Approved 8429	THIODERON Approved Use For the treatment of breast cancer and anemia associated with renal failure. Launch Date 1979

PubMed

Title	Date	PubMed
2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer.	1978 Feb	343913
Steroid hormone receptors and clinical usefulness in human breast cancer.	1980 Dec 15	7448732
A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.	1985 Dec 1	2932213
Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients.	1989	2474097
Determination of mepitiostane metabolites in human urine by liquid chromatography/tandem mass spectrometry for sports drug testing.	2015 Nov 10	26247800

Patents

Sample Use Guides

In Vivo Use Guide

The drug is administered orally twice a day. The recommended daily dose is 20 mg.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:46:29 GMT 2023` Edited by `admin` on `Fri Dec 15 16:46:29 GMT 2023`
Record UNII	O00404969K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEPITIOSTANE

Official Name

English

THIODERON

Brand Name

English

MEPITIOSTANE [MART.]

Common Name

English

CYCLOPENTANONE 2.ALPHA.,3.ALPHA.-EPITHIO-5.ALPHA.-ANDROSTAN-17.BETA.-YL METHYL ACETAL

Systematic Name

English

mepitiostane [INN]

Common Name

English

Mepitiostane [WHO-DD]

Common Name

English

MEPITIOSTANE [MI]

Common Name

English

MEPITIOSTANE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C481